- Male or female patients of 18 years or more presenting with chest pain will be
potentially eligible for inclusion in the study if they satisfy the criteria for
unstable coronary artery disease per the investigator's routine practice and have
received at least one injection of Fragmin (dalteparin sodium) as part of routine
clinical practice and is expected to be treated conservatively (without PCI or CABG
within 48 hours) during the index hospitalization.
- Evidence of a personally signed and dated informed consent document indicating that
the subject (or a legally acceptable representative) has been informed of all
pertinent aspects of the study.
- Patients who are contraindicated to receive this agent per the local approved